Gold bars to be exempt from tariffs, White House clarifies
NEW YORK - PAVmed Inc. (NASDAQ:PAVM), a commercial-stage medical technology company with a market capitalization of $10.17 million, announced Wednesday it has received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement.
The company now has until January 19, 2026, to meet the requirement, according to a press release statement. During this extension period, PAVmed must maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days to regain compliance.
The notification has no immediate effect on the listing or trading of PAVmed’s shares, which will continue to trade on the Nasdaq Capital Market under the symbol "PAVM."
PAVmed operates across medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (NASDAQ:LUCD), markets tools for early detection of esophageal precancer, while another subsidiary, Veris Health, focuses on enhanced personalized cancer care through remote patient monitoring.
The company stated it intends to take appropriate actions to cure the deficiency and regain compliance before the end of the compliance period.
In other recent news, PAVmed Inc. reported strong financial results for the first quarter of 2025, with a GAAP net income of $18.6 million and a positive earnings per share (EPS). The company also announced strategic operational changes, including a notable reduction in liabilities. Additionally, PAVmed expressed a promising outlook for its product pipeline, indicating potential future growth. These developments highlight the company’s robust financial health and strategic focus. Despite these positive results, the stock experienced a slight decline in premarket trading. Investors may find these recent developments significant as they consider the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.